Effectiveness and Safety of Simnotrelvir/Ritonavir and Nirmatrelvir/Ritonavir in the Treatment of Moderate to Severe COVID‐19
This is the first study comparing the effectiveness of simnotrelvir/ritonavir and nirmatrelvir/ritonavir in moderate and severe COVID-19 patients. Patients who received simnotrelvir/ritonavir exhibited shorter hospitalization. Disease progression, viral clearance times, and symptom resolution time were similar between the two groups.
Authors
- Xiaoqing Lin (ORCID: https://orcid.org/0000-0003-4986-2835)
- Fang Cheng (ORCID: https://orcid.org/0009-0003-1834-1153)
- Qiang Zhang (ORCID: https://orcid.org/0000-0002-3680-6394)
- Te Wu
- Xin Chen (ORCID: https://orcid.org/0000-0001-8305-6592)
- Shi‐Lin Zheng
- Ji‐Chan Shi
- Xiangao Jiang (ORCID: https://orcid.org/0009-0005-9631-0015)
Institutions
- Wenzhou Medical University (CN)
- Wenzhou Central Hospital (CN)
Publication Details
- Journal
- Immunity Inflammation and Disease
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/iid3.70174
- Citations
- 4
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.58